Pediatrics Doctors in Hugo, MN Accepting Medicare
2 Pediatrics doctors found. Showing 1 - 2
 Dr. Neeti Kambale, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 14701 Victor Hugo Blvd N, Hugo, MN 55038 Phone: 651-426-1141 Fax: 651-426-1705 |
Cynthia Krull, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 14701 Victor Hugo Blvd N, Hugo, MN 55038 Phone: 651-426-1141 Fax: 651-426-1705 |
News Archive
NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents
NiKem Research is pleased to announce that it has received on March 29th 2010, from the Italian Ministry of Health (Decree N. 69/2010-B), the authorization to perform acute and sub-chronic toxicology studies (upto 28 days) in all rodent species for preliminary safety evaluation of novel chemical entities (NCEs). Toxicokinetic (TK) studies are also allowed to correlate plasma and/or organ exposure of NCEs (and metabolites) to tolerated doses in toxicology studies.
Julphar's DEXCOM G4 PLATINUM CGM system now available in GCC
The Julphar revolutionary real-time continuous glucose monitoring device (CGM), DEXCOM G4 PLATINUM is now available in UAE, KSA, Kuwait and Oman and will soon be available in Qatar, Bahrain and Lebanon. With this unique technology, diabetic patients can easily and conveniently monitor their glucose level around the clock.
Penn researchers show that canine X-linked retinitis pigmentosa can be cured over the long term
Three years ago, a team from the University of Pennsylvania announced that they had cured X-linked retinitis pigmentosa, a blinding retinal disease, in dogs. Now they've shown that they can cure the canine disease over the long term, even when the treatment is given after half or more of the affected photoreceptor cells have been destroyed.
IMUC's ICT-107 vaccine product candidate targets cancer stem cells
ImmunoCellular Therapeutics today announced the results of a study in which it was shown that certain specific antigens are highly expressed on cancer stem cells (CSCs). This suggests that IMUC's lead cancer vaccine product candidate ICT-107, which targets those antigens, may effectively target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs that are widely believed to give rise to them and cause their recurrence.
New research highlights urgent need to address distress in long-term melanoma survivors
More than one-third of Queensland melanoma survivors are suffering clinically significant psychological distress, despite the high survival rate associated with the cancer.
› Verified 3 days ago